Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis

International Journal of Tuberculosis and Lung Disease

Volumn 10, Issue 10, 2006, Pages 1127-1132

  Sichletidis, Lazaros ^a,b   Settas, L ^a   Spyratos, D ^a   Chloros, D ^a   Patakas, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b G PAPANICOLAOU HOSPITAL   (Greece)

Author keywords

Adalimumab; Etanercept; Infliximab; Rheumatoid arthritis; TNF; Tuberculosis

Indexed keywords

ADALIMUMAB; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; ISONIAZID; METHOTREXATE; PREDNISOLONE; RIFAMPICIN; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ADULT; AGED; ARTICLE; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GREECE; HUMAN; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MORBIDITY; PRIORITY JOURNAL; RHEUMATIC DISEASE; THORAX RADIOGRAPHY; TUBERCULIN TEST; UNIVERSITY HOSPITAL;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ANTITUBERCULAR AGENTS; ARTHRITIS; ARTHRITIS, RHEUMATOID; COMORBIDITY; FEMALE; GREECE; HUMANS; IMMUNOGLOBULIN G; INCIDENCE; ISONIAZID; MALE; MIDDLE AGED; RECEPTORS, TUMOR NECROSIS FACTOR; RETROSPECTIVE STUDIES; RIFAMPIN; SPONDYLITIS, ANKYLOSING; TUBERCULOSIS; TUBERCULOSIS, PULMONARY;

EID: 33749475525     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Haworth C, Berennan F M, Chantry D, Turner M, Maini R N, Feldmann M. Expression of granulocyte-macrophage colony-stimulating factor in rheumatoid arthritis: regulation by tumor necrosis factor-a. Fur J Immunol 1991; 21: 2575-2579.
2. Butler D M, Maini R N, Feldmann M, Brennan F M. Modulation of proinflammatory cytokine release in rheumatoid synovial membrane cell cultures: comparison of monoclonal anti TNF-α antibody with interleukin-1 receptor antagonist. Eur Cytokine Netw 1995; 6: 225-230.
3. Shingu M, Nagai Y, Isayama T, Naono T, Nobunaga M, Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin Exp Immunol 1993; 94: 145-149.
4. Choy E H S, Panayi G S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-915.
5. Emery P, Reginster J Y, Appelboom T, et al. WHO collaborating centre consensus meeting on anti-cytokine therapy in rheumatoid arthritis. Rheumatology 2001; 40: 699-702.
6. Finckh A, Simard J F, Duryea J, et al. The effectiveness of antitumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. Arthritis Rheum 2006; 54: 54-59.
7. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomized controlled multicentre trial. Lancet 2002; 359: 1187-1193.
8. Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. Arthritis Rheum 2005; 53: 856-863.
9. Keystone E C, Kavanaugh A F, Sharp J T, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. Arthritis Rheum 2004; 50: 1400-1411.
10. Schuma A A, Megeff C. New drugs for the treatment of rheumatoid arthritis. Am J Health Syst Pharm 2000; 57: 225-234.
11. Kornbluth A. Infliximab approved for use in Crohn's disease: a report on the FDA GI Advisory Committee conference. Inflamm Bowel Dis 1998; 4: 328-329.
12. Kisich K O, Higgins M, Diamond G, Heifets L. Tumor necrosis factor-alpha stimulates killing of Mycobacterium tuberculosis by human neutrophils. Infect Immun 2002; 70: 4591-4599.
13. Flynn J L, Goldstein M M, Chan J, et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995; 2: 561-572.
14. Flynn J L, Chan J. Immunology of tuberculosis. Annu Rev Immunol 2001; 19: 93-129.
15. Roach D R, Bean A G D, Demangel C, France M P, Briscoe H, Britton W J. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002; 168: 4620-4627.
16. Johnson C M, Cooper A M, Frank A A, Orme I M. Adequate expression of protective immunity in the absence of granuloma formation in Mycobacterium tuberculosis-infected mice with a disruption in the intracellular adhesion molecule 1 gene. Infect Immun 1998; 66: 1666-1670.
17. Bean A G D, Roach D R, Briscoe H, et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999; 162: 3504-3511.
18. Senaldi G, Yin S, Shaklee C L, Piguet P F, Mak T W, Ulich T R. Corynebacterium parvum- and Mycobacterium bovis bacillus Calmette-Guerin-induced granuloma formation is inhibited in TNF receptor I (TNV-RI) knockout mice and by treatment with soluble TNF-RI. J Immunol 1996; 157: 5022-5026.
19. Keane J, Gershon S K, Wise R P, et al. Tuberculosis associated with infliximab, a tumor necrosis factor-α neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
20. Keane J, Gershon S K, Braun M M. Tuberculosis and treatment with infliximab. N Engl J Med 2002; 346: 623-626.
21. Gomez-Reino J J, Carmona L, Valverde V R, Mola E M, Montero M D. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk. Arthritis Rheum 2003; 48: 2122-2127.
22. Giles J T, Bathon J M, Serious infections associated with anticytokine therapies in the rheumatic diseases. J Intensive Care Med 2004; 19: 320-334.
23. Carmona L, Gonzalez-Alvaro I, Sanmarti R, et al. Rheumatoid arthritis is associated to a four-fold increase in tuberculosis infection incidence in the pre-biologics era. Arthritis Rheum 2001; 44 (Suppl 9): S173.
24. Wolfe F, Flowers N, Anderson J, Urbansky K. Tuberculosis rates are not increased in rheumatoid arthritis (RA). Arthritis Rheum 2001; 44 (Suppl 9): S105.
25. Ruderman E M, Markenson J. Granulomatous infections and tumour necrosis factor antagonist therapies update through June 2002. Arthritis Rheum 2003; 48 (Suppl 9): S241.
26. US Food and Drug Administration Arthritis Advisory Committee. Briefing information. 4 March 2003. http://www.fda.gov/ ohrms/dockets/ac/03/briefing/ 3930b1.htm Accessed April 2006.
27. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004; 50: 372-379.
28. World Health Organization. WHO Report 2006. Global tuberculosis control: surveillance, planning, financing. WHO/HTM/ TB/2006.362. Geneva, Switzerland: WHO, 2006. http://www. who.int/tb/publications/global_report/2006/pdf/eur.pdf Accessed May 2006.
29. Ruiz J P, Centeno N O, Alvarez E R. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid (letter). J Rheumat 2003; 30: 1657-1658.
30. Keane J. TNF-blocking agents and tuberculosis: new drugs illuminate an old topic. Rheumatology 2005; 44: 714-720.
31. Horsburg C R Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004; 350: 2060-2067.
32. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000; 161: 1376-1395.
33. Lee A M, Mennone J Z, Jones R C, Paul W S. Risk factors for hepatotoxicity associated with rifampin and pyrazinamide for the treatment of latent tuberculosis infection: experience from three public health tuberculosis clinics. Int J Tuberc Lung Dis 2002; 6: 995-1000.
34. British Thoracic Society Guidelines. BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-α treatment. Thorax 2005; 60: 800-805.
35. Rieder H L, Snider D E Jr, Cauthen G M. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 1990; 141: 347-351.